Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Medtronic
Moodys
Dow

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Loteprednol Etabonate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00366691 Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Completed Medical University of South Carolina Phase 4 2006-02-01 The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
NCT00420628 Pediatric Zylet Safety and Efficacy Study Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
NCT00447577 Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2007-01-01 The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
NCT00560638 Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Completed Bausch & Lomb Incorporated Phase 2 2005-11-01 This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
NCT00645671 Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery Completed Bausch & Lomb Incorporated Phase 3 2008-03-01 To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
NCT00689078 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed ORA, Inc. Phase 4 2008-05-01 The purpose of the study is to determine whether prednisolone acetate 1% ophthalmic suspension is effective in preventing signs and symptoms of allergic conjunctivitis in comparison with prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension and placebo in a modified conjunctival allergen challenge (CAC) model.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Loteprednol Etabonate

Condition Name

Condition Name for Loteprednol Etabonate
Intervention Trials
Inflammation 5
Pain 4
Cataract 4
Keratoconjunctivitis Sicca 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Loteprednol Etabonate
Intervention Trials
Inflammation 13
Cataract 9
Dry Eye Syndromes 7
Conjunctivitis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Loteprednol Etabonate

Trials by Country

Trials by Country for Loteprednol Etabonate
Location Trials
United States 123
Singapore 2
Korea, Republic of 2
Israel 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Loteprednol Etabonate
Location Trials
California 11
New York 11
Massachusetts 7
Missouri 7
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Loteprednol Etabonate

Clinical Trial Phase

Clinical Trial Phase for Loteprednol Etabonate
Clinical Trial Phase Trials
Phase 4 13
Phase 3 14
Phase 2 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Loteprednol Etabonate
Clinical Trial Phase Trials
Completed 29
Recruiting 6
Unknown status 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Loteprednol Etabonate

Sponsor Name

Sponsor Name for Loteprednol Etabonate
Sponsor Trials
Bausch & Lomb Incorporated 20
Kala Pharmaceuticals, Inc. 7
University of Michigan 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Loteprednol Etabonate
Sponsor Trials
Industry 31
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKesson
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.